NO20033443L - Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser - Google Patents

Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser

Info

Publication number: NO20033443L
Authority: NO; Norway
Prior art keywords: prevention; treatment; binding agents; skin disorders; disorders
Prior art date: 2001-02-01

Application number

NO20033443A

Other languages

English (en)

Other versions

NO20033443D0 (no

Inventor

Akshay K Vaishnaw

Kevin D Cooper

Daniel Shrager

Thomas S Mccormick

Original Assignee

Univ Cleveland Hospitals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-01

Filing date

2003-08-01

Publication date

2003-09-30

2003-08-01 Application filed by Univ Cleveland Hospitals filed Critical Univ Cleveland Hospitals

2003-08-01 Publication of NO20033443D0 publication Critical patent/NO20033443D0/no

2003-09-30 Publication of NO20033443L publication Critical patent/NO20033443L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20033443A 2001-02-01 2003-08-01 Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser NO20033443L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26596401P	2001-02-01	2001-02-01
PCT/US2002/002314 WO2002060480A1 (en)	2001-02-01	2002-01-25	Methods for treating or preventing skin disorders using cd2-binding agents

Publications (2)

Publication Number	Publication Date
NO20033443D0 NO20033443D0 (no)	2003-08-01
NO20033443L true NO20033443L (no)	2003-09-30

Family

ID=23012611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033443A NO20033443L (no)	2001-02-01	2003-08-01	Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser

Country Status (22)

Country	Link
US (3)	US20040170635A1 (no)
EP (1)	EP1409015A4 (no)
JP (1)	JP2004527477A (no)
KR (1)	KR20040043112A (no)
CN (1)	CN1527723A (no)
AR (1)	AR035079A1 (no)
BG (1)	BG108020A (no)
BR (1)	BR0206905A (no)
CA (1)	CA2436411A1 (no)
CZ (1)	CZ20032081A3 (no)
EA (1)	EA200300849A1 (no)
EE (1)	EE200300366A (no)
GE (1)	GEP20063828B (no)
HU (1)	HUP0303826A2 (no)
IS (1)	IS6894A (no)
MX (1)	MXPA03006919A (no)
NO (1)	NO20033443L (no)
PL (1)	PL368556A1 (no)
SK (1)	SK9722003A3 (no)
WO (1)	WO2002060480A1 (no)
YU (1)	YU61203A (no)
ZA (1)	ZA200305936B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6764681B2 (en)	1991-10-07	2004-07-20	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
TR200100607T2 (tr) *	1998-08-31	2001-06-21	Biogen, Inc.	Bellek efektör T-hücrelerinin modülasyonu için yöntem ve bileşimler
AU2002322478A1 (en) *	2001-03-02	2002-12-16	Medimmune, Inc.	Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2003009740A2 (en)	2001-07-24	2003-02-06	Biogen Idec Ma Inc.	Methods for treating or preventing sclerotic disorders using cd2-binding agents
US11517612B2 (en)	2016-11-18	2022-12-06	Nepsone Ehf	Methods of treating inflammatory skin disorders
DK1556020T3 (da)	2002-08-12	2009-06-22	Birkir Sveinsson	Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
GB0307864D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
US20070172478A1 (en) *	2004-02-06	2007-07-26	Astellas Us Llc	Methods of treating skin disorders
EP1747291A2 (en) *	2004-05-04	2007-01-31	Genaissance Pharmaceuticals, Inc.	Haplotype markers and methods of using the same to determine response to treatment
WO2005115436A1 (en) *	2004-05-07	2005-12-08	Astellas Us Llc	Soluble lfa-3 polypeptide for treating viral disorders
US20060078580A1 (en) *	2004-10-08	2006-04-13	Mediquest Therapeutics, Inc.	Organo-gel formulations for therapeutic applications
CN101113459A (zh) *	2007-07-16	2008-01-30	东莞太力生物工程有限公司	一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
US9289469B2 (en)	2009-09-10	2016-03-22	Mayo Foundation For Medical Education And Research	Depleting immunosuppressive monocytes within a mammal
WO2011059926A2 (en)	2009-11-10	2011-05-19	Mayo Foundation For Medical Eduction And Research	Methods and materials for treating renal cell carcinoma
WO2014025198A2 (ko) *	2012-08-09	2014-02-13	주식회사 한독	Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014078272A1 (en)	2012-11-13	2014-05-22	Mayo Foundation For Medical Education And Research	Methods and materials for assessing immune system profiles
US10094835B2 (en)	2013-05-09	2018-10-09	Mayo Foundation For Medical Education And Research	Treating patients based on immune subtypes
JP2021519758A (ja) *	2018-03-29	2021-08-12	ファイザーインコーポレイティッド	Ｌｆａ３バリアントならびにその組成物および使用法
WO2023224980A1 (en) *	2022-05-17	2023-11-23	The Uab Research Foundation	Methods and compositions for treating or preventing inflammatory skin disorders
WO2024050455A2 (en) *	2022-08-31	2024-03-07	Heitmeyer Jamie Nicole	Anti-rhd antibodies for treating inflammatory dermal condition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6764681B2 (en) *	1991-10-07	2004-07-20	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2112335T3 (es) *	1991-10-07	1998-04-01	Biogen Inc	Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3.
US6162432A (en) *	1991-10-07	2000-12-19	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5817311A (en) *	1993-03-05	1998-10-06	Universite Catholique De Louvain	Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5951983A (en) *	1993-03-05	1999-09-14	Universite Catholique De Louvain	Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) *	1993-03-05	1998-03-24	Universite Catholique Delouvain	LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
TR200100607T2 (tr) *	1998-08-31	2001-06-21	Biogen, Inc.	Bellek efektör T-hücrelerinin modülasyonu için yöntem ve bileşimler

2002
- 2002-01-25 SK SK972-2003A patent/SK9722003A3/sk unknown
- 2002-01-25 EP EP02704253A patent/EP1409015A4/en not_active Withdrawn
- 2002-01-25 BR BR0206905-9A patent/BR0206905A/pt not_active Application Discontinuation
- 2002-01-25 HU HU0303826A patent/HUP0303826A2/hu unknown
- 2002-01-25 JP JP2002560671A patent/JP2004527477A/ja not_active Withdrawn
- 2002-01-25 CA CA002436411A patent/CA2436411A1/en not_active Abandoned
- 2002-01-25 EA EA200300849A patent/EA200300849A1/ru unknown
- 2002-01-25 PL PL02368556A patent/PL368556A1/xx not_active Application Discontinuation
- 2002-01-25 YU YU61203A patent/YU61203A/sh unknown
- 2002-01-25 KR KR10-2003-7010218A patent/KR20040043112A/ko not_active Withdrawn
- 2002-01-25 MX MXPA03006919A patent/MXPA03006919A/es unknown
- 2002-01-25 US US10/470,764 patent/US20040170635A1/en not_active Abandoned
- 2002-01-25 GE GE5273A patent/GEP20063828B/en unknown
- 2002-01-25 CN CNA028079191A patent/CN1527723A/zh active Pending
- 2002-01-25 CZ CZ20032081A patent/CZ20032081A3/cs unknown
- 2002-01-25 WO PCT/US2002/002314 patent/WO2002060480A1/en not_active Ceased
- 2002-01-25 EE EEP200300366A patent/EE200300366A/xx unknown
- 2002-01-28 AR ARP020100293A patent/AR035079A1/es unknown
- 2002-12-26 US US10/329,599 patent/US20030185824A1/en not_active Abandoned
2003
- 2003-07-22 BG BG108020A patent/BG108020A/bg unknown
- 2003-07-25 IS IS6894A patent/IS6894A/is unknown
- 2003-07-31 ZA ZA2003/05936A patent/ZA200305936B/en unknown
- 2003-08-01 NO NO20033443A patent/NO20033443L/no unknown
2005
- 2005-12-20 US US11/312,627 patent/US20070031443A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040170635A1 (en)	2004-09-02
US20070031443A1 (en)	2007-02-08
HUP0303826A2 (hu)	2004-03-01
IS6894A (is)	2003-07-25
CA2436411A1 (en)	2002-08-08
BG108020A (bg)	2004-03-31
WO2002060480A1 (en)	2002-08-08
EA200300849A1 (ru)	2004-02-26
AR035079A1 (es)	2004-04-14
EP1409015A4 (en)	2006-04-12
WO2002060480A9 (en)	2004-05-27
CN1527723A (zh)	2004-09-08
PL368556A1 (en)	2005-04-04
KR20040043112A (ko)	2004-05-22
NO20033443D0 (no)	2003-08-01
EE200300366A (et)	2003-12-15
EP1409015A1 (en)	2004-04-21
CZ20032081A3 (cs)	2004-01-14
MXPA03006919A (es)	2004-06-02
SK9722003A3 (en)	2004-05-04
JP2004527477A (ja)	2004-09-09
ZA200305936B (en)	2005-01-26
GEP20063828B (en)	2006-05-10
BR0206905A (pt)	2004-07-06
YU61203A (sh)	2006-05-25
US20030185824A1 (en)	2003-10-02

Publication	Publication Date	Title
NO20033443D0 (no)	2003-08-01	Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
NO20041588L (no)	2004-04-19	Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
ES2414872T8 (es)	2014-11-06	Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
EP1438062A4 (en)	2005-06-01	METHOD AND COMPOSITIONS FOR TREATING SKIN Lions
PT1181027E (pt)	2004-09-30	Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
EE200100480A (et)	2002-12-16	Ksenoon kasutamiseks närvimürgistuste ravis
BR0211251B1 (pt)	2013-09-17	composição para o tratamento de cabelo e/ou couro cabeludo.
IL159422A0 (en)	2004-06-01	Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
NO994014D0 (no)	1999-08-19	Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
NO20022680L (no)	2002-08-12	Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
EP1392292A4 (en)	2004-08-11	PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
NO20043370L (no)	2004-09-28	N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
NO20033803L (no)	2003-10-10	Karbamatforbindelser for anvendelse ved prevensjon eller terapi av bevegelseslidelser
AU2002345255A1 (en)	2003-01-21	Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
NO20033798D0 (no)	2003-08-26	Karbamatforbindelser for bruk ved prevensjon eller terapi av neurodegenerative lidelser
NO20001412D0 (no)	2000-03-17	Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is)	2003-09-24	Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20054913D0 (no)	2005-10-24	Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
PT1381620E (pt)	2006-06-30	Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes
ATE314064T1 (de)	2006-01-15	L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
EE200300057A (et)	2004-12-15	Koostis vähi profülaktikaks ja raviks
EP1539100A4 (en)	2006-01-18	COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
HUP0204209A3 (en)	2005-03-29	Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms